title: [The combined drug ascoril in the treatment of patients with chronic obstructive pulmonary disease concurrent with coronary heart disease].
abstract: OBJECTIVE
  To evaluate the clinical efficacy of the combined drug ascoril (Glenmark, India) in patients with grade I-Ii chronic obstructive pulmonary disease (COPD) concurrent with coronary heart disease (CHD).
  
  
  METHODS
  Sixty patients, including 12 (20%) women and 48 (80%) men, aged 43 to 68 years (mean age 55.1 +9.9 years), with COPD were examined. The patients were divided into 2 groups. Group 1 used the combined broncholytic and expectorant drug ascoril and Group 2 took mucolytic agent ambroxol. The follow-up period was 7 days.
  
  
  RESULTS
  On day 2 of ascoril treatment, all the patients showed a significant reduction in the intensity of cough that was completely relieved in 26 (87%) patients by treatment day 7. Prior to ascoril treatment, heart rate (HR) was 64.4+/-5.5 beats/min. A significant increase in HR to 72.7+/-10.1 beats/min was observed 20 min after the first drug intake (p < 0.05) and a decrease to 68.6+/-10.5 beats/min was seen after 60 min. On treatment day 7, HR was 63.0+/-6.5 beats/min, which was similar to that before ascoril treatment (p = 0.6).
  
  
  CONCLUSIONS
  In the patients with COPD concurrent with CHD, the combined drug ascoril exerts broncholytic and expectorant effects, with no pronounced negative action on HR.
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Grigor'eva
authors.forename: A N
authors.initials: AN
authors.lastname: Kuznetsov
authors.forename: T V
authors.initials: TV
authors.lastname: Koroleva
authors.forename: M E
authors.initials: ME
authors.lastname: Koroleva
mesh_terms: D000328:Adult; D000368:Aged; D000551:Ambroxol / Q000008:administration & dosage / Q000494:pharmacology*; D000996:Antitussive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015897:Comorbidity; D003327:Coronary Disease / Q000188:drug therapy* / Q000453:epidemiology; D003915:Dextromethorphan / Q000008:administration & dosage / Q000494:pharmacology*; D005100:Expectorants / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000453:epidemiology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000996:Antitussive Agents; D005100:Expectorants; D000551:Ambroxol; D003915:Dextromethorphan